ERBB2 and neoplasm: Taken together, our results indicate that ErbB2-CAR redirection of CIK cells improves the cytotoxicity of immune effector cells against ErbB2-positive tumor targets compared to WT CIK cells, implying that this therapy may represent a step forward in the treatment of resistant, relapsed and advanced STS.